Tharimmune (THAR) 10-Q2023 Q1 Quarterly report

Filed: 19 May 23, 7:26pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: ABSI, affinity, afforded, amino, antibody, assuming, bi, bind, binding, biologic, Biomedical, bispecific, bound, CDR, challenging, coated, committed, comparison, complementary, comprised, country, create, delivering, department, digit, discover, doubt, entry, epidermal, equivalent, ErbB, exceeded, exclusive, factor, failure, focused, gain, gastric, growing, half, heightened, history, human, IO, knob, knowledge, larger, long, longer, low, Minotaur, MINT, monoclonal, OmniAb, ovarian, par, partner, patent, pay, payload, Picobody, preferentially, premium, prevailing, procedure, promote, protein, Quatrabody, rapidly, ratio, receptor, reclassified, ROS, royalty, Science, Secretary, shelf, single, subsidiary, surface, ThinkEquity, tied, tightly, TNBC, trispecific, ultralong, unique, unreachable, Valid, validated, weighing

Removed: adequate, adjusting, artificial, call, castration, cease, codified, curtailed, deduction, degree, dividend, extinguishment, finance, fluid, function, hand, higher, hiring, identify, implication, Imputation, increasing, increment, intelligence, light, mature, medicine, modification, modified, modulator, nature, noteholder, oxygen, pediatric, precision, presentation, prostate, put, ranged, reactive, rolled, specific, thereon, Trident, TridentAI, unclear, variability, varied

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

THAR similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Randy Milby, Chief Executive Officer of Hillstream BioPharma, Inc. (the “Company”), hereby certifies that based on the undersigned’s knowledge:

	1.	The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 19, 2023	/s/ Randy Milby
	Randy Milby
	Chief Executive Officer
	(Principal Executive Officer)